MTOR and early-onset autosomal dominant Alzheimer disease: Flozins, by restoring the circadian rhythm of mTOR activity, seem to bring benefits in patients with Alzheimer’s Disease according to “Type 3 Diabetes Hypothesis”, “Mitochondrial Cascade Hypothesis” and “Endo-Lysosomal Dysfunction Hypothesis” [105].